Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday.

Regeneron Pharmaceuticals said it will acquire substantially all of 23andMe's assets for $256 million after coming out on top at a bankruptcy auction for the once-sizzling DNA-testing startup.

(Reuters) -Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe Holding for $256 million through a ...

Regeneron Pharmaceuticals (NASDAQ:REGN) will buy substantially all assets of genetic testing firm 23andMe for a purchase pric ...

This was the stock's second consecutive day of gains.

The jury after just over half a day of deliberations found Amgen Inc. liable on 10 of the 11 claims in the complaint, including monopolization and unreasonable restraint of trade in violation of the ...

The chronic pruritus market is expected to grow across the 7MM, driven by the introduction of innovative therapies like ...